Mabpharm (2181.HK) Stock Price

Mabpharm Price

CLOSED
0.37CNY-0.0039 (-1.05 %)
Market closed

Revenue has compounded at 84.5% per year over the past 8 years to 730.71 M CNY. Mabpharm's net margin stands at 8.8%, up from -352.0% several years earlier. The stock trades about 14% above its 52-week low.

Mabpharm stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Mabpharm over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Mabpharm stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Mabpharm's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Mabpharm Stock Price History
DateMabpharm Price
8/5/20260.37 CNY
8/4/20260.37 CNY
8/3/20260.34 CNY
7/31/20260.34 CNY
7/30/20260.35 CNY
7/29/20260.35 CNY
7/28/20260.35 CNY
7/27/20260.35 CNY
7/24/20260.35 CNY
7/23/20260.35 CNY
7/22/20260.35 CNY
7/21/20260.35 CNY
7/20/20260.35 CNY
7/17/20260.35 CNY
7/16/20260.38 CNY
7/15/20260.34 CNY
7/14/20260.34 CNY
7/13/20260.37 CNY
7/10/20260.37 CNY
7/9/20260.34 CNY
7/8/20260.34 CNY
7/7/20260.35 CNY
7/6/20260.37 CNY
7/3/20260.34 CNY
7/2/20260.36 CNY
6/30/20260.36 CNY
6/29/20260.36 CNY
6/26/20260.37 CNY
6/25/20260.38 CNY
6/24/20260.38 CNY
6/23/20260.36 CNY
6/22/20260.32 CNY
6/18/20260.33 CNY
6/17/20260.33 CNY
6/16/20260.33 CNY
6/15/20260.33 CNY
6/12/20260.33 CNY
6/11/20260.33 CNY
6/10/20260.32 CNY
6/9/20260.33 CNY
6/8/20260.33 CNY
6/5/20260.35 CNY
6/4/20260.36 CNY
6/3/20260.37 CNY
6/2/20260.39 CNY
6/1/20260.35 CNY
5/29/20260.34 CNY
5/28/20260.35 CNY
5/27/20260.35 CNY
5/26/20260.37 CNY
5/22/20260.38 CNY
5/21/20260.38 CNY
5/20/20260.39 CNY
5/19/20260.39 CNY
5/18/20260.44 CNY
5/15/20260.44 CNY
5/14/20260.44 CNY
5/13/20260.42 CNY
5/12/20260.43 CNY
5/11/20260.39 CNY
5/8/20260.40 CNY
5/7/20260.42 CNY
5/6/20260.39 CNY
5/5/20260.39 CNY
5/4/20260.39 CNY
4/30/20260.39 CNY
4/29/20260.40 CNY
4/28/20260.40 CNY
4/27/20260.40 CNY
4/24/20260.39 CNY
4/23/20260.39 CNY
4/22/20260.39 CNY
4/21/20260.39 CNY
4/20/20260.39 CNY
4/17/20260.39 CNY
4/16/20260.38 CNY
4/15/20260.38 CNY
4/14/20260.39 CNY
4/13/20260.42 CNY
4/10/20260.40 CNY
4/9/20260.38 CNY
4/8/20260.42 CNY
4/2/20260.43 CNY
4/1/20260.46 CNY
3/31/20260.43 CNY
3/30/20260.46 CNY
3/27/20260.48 CNY
3/26/20260.49 CNY
3/25/20260.49 CNY
3/24/20260.49 CNY
3/23/20260.46 CNY
3/20/20260.45 CNY
3/19/20260.53 CNY
3/18/20260.47 CNY
3/17/20260.52 CNY
3/16/20260.62 CNY
3/13/20260.61 CNY
3/12/20260.44 CNY
3/11/20260.44 CNY
3/10/20260.37 CNY
3/9/20260.36 CNY
3/6/20260.36 CNY
3/5/20260.35 CNY
3/4/20260.35 CNY
3/3/20260.37 CNY
3/2/20260.37 CNY
2/27/20260.37 CNY
2/26/20260.37 CNY
2/25/20260.37 CNY
2/24/20260.37 CNY
2/23/20260.39 CNY
2/20/20260.44 CNY
2/16/20260.44 CNY
2/13/20260.44 CNY
2/12/20260.44 CNY
2/11/20260.44 CNY
2/10/20260.43 CNY
2/9/20260.43 CNY
2/6/20260.43 CNY
2/5/20260.45 CNY
2/4/20260.45 CNY
2/3/20260.45 CNY
2/2/20260.46 CNY
1/30/20260.47 CNY
1/29/20260.46 CNY
1/28/20260.46 CNY
1/27/20260.43 CNY
1/26/20260.43 CNY
1/23/20260.43 CNY
1/22/20260.44 CNY
1/21/20260.44 CNY
1/20/20260.45 CNY
1/19/20260.43 CNY
1/16/20260.44 CNY
1/15/20260.44 CNY
1/14/20260.45 CNY
1/13/20260.45 CNY
1/12/20260.47 CNY
1/9/20260.48 CNY
1/8/20260.45 CNY
1/7/20260.45 CNY
1/6/20260.43 CNY
1/5/20260.43 CNY
1/2/20260.43 CNY
12/31/20250.43 CNY
12/30/20250.43 CNY
12/29/20250.47 CNY
12/24/20250.47 CNY
12/23/20250.47 CNY
12/22/20250.48 CNY
12/19/20250.46 CNY
12/18/20250.46 CNY
12/17/20250.46 CNY
12/16/20250.46 CNY
12/15/20250.49 CNY
12/12/20250.49 CNY
12/11/20250.49 CNY
12/10/20250.50 CNY
12/9/20250.48 CNY
12/8/20250.51 CNY
12/5/20250.51 CNY
12/4/20250.48 CNY
12/3/20250.50 CNY
12/2/20250.50 CNY
12/1/20250.47 CNY
11/28/20250.46 CNY
11/27/20250.45 CNY
11/26/20250.45 CNY
11/25/20250.45 CNY
11/24/20250.45 CNY
11/21/20250.45 CNY
11/20/20250.45 CNY
11/19/20250.45 CNY
11/18/20250.45 CNY
11/17/20250.45 CNY
11/14/20250.45 CNY
11/13/20250.45 CNY
11/12/20250.45 CNY
11/11/20250.46 CNY
11/10/20250.46 CNY
11/7/20250.45 CNY
11/6/20250.45 CNY
11/5/20250.46 CNY
11/4/20250.45 CNY
11/3/20250.45 CNY
10/31/20250.45 CNY
10/30/20250.49 CNY
10/28/20250.52 CNY
10/27/20250.52 CNY
10/24/20250.52 CNY
10/23/20250.52 CNY
10/22/20250.54 CNY
10/21/20250.57 CNY
10/20/20250.55 CNY
10/17/20250.53 CNY
10/16/20250.53 CNY
10/15/20250.53 CNY
10/14/20250.53 CNY
10/13/20250.58 CNY
10/10/20250.59 CNY
10/9/20250.56 CNY
10/8/20250.58 CNY
10/6/20250.55 CNY
10/3/20250.56 CNY
10/2/20250.53 CNY
9/30/20250.55 CNY
9/29/20250.55 CNY
9/26/20250.62 CNY
9/25/20250.63 CNY
9/24/20250.64 CNY
9/23/20250.64 CNY
9/22/20250.64 CNY
9/19/20250.68 CNY
9/18/20250.62 CNY
9/17/20250.66 CNY
9/16/20250.68 CNY
9/15/20250.69 CNY
9/12/20250.69 CNY
9/11/20250.68 CNY
9/10/20250.68 CNY
9/9/20250.68 CNY
9/8/20250.68 CNY
9/5/20250.68 CNY
9/4/20250.69 CNY
9/3/20250.70 CNY
9/2/20250.69 CNY
9/1/20250.72 CNY
8/29/20250.69 CNY
8/28/20250.63 CNY
8/27/20250.64 CNY
8/26/20250.67 CNY
8/25/20250.68 CNY
8/22/20250.70 CNY
8/21/20250.69 CNY
8/20/20250.70 CNY
8/19/20250.70 CNY
8/18/20250.69 CNY
8/15/20250.64 CNY
8/14/20250.67 CNY
8/13/20250.58 CNY
8/12/20250.57 CNY
8/11/20250.61 CNY
8/8/20250.50 CNY
8/7/20250.43 CNY
Access this data via the Eulerpool API
Get Free API Key

Mabpharm Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
82.88 M CNY
-297.52 M CNY
-291.74 M CNY
Jan 1, 2022
55.92 M CNY
-226.25 M CNY
-210.62 M CNY
Jan 1, 2023
87.16 M CNY
-199.78 M CNY
-209.36 M CNY
Jan 1, 2024
258.23 M CNY
-117.91 M CNY
-127.95 M CNY
Jan 1, 2025
730.71 M CNY
5.43 M CNY
64.62 M CNY
Jan 1, 2026 (e)
129.69 M CNY
-89.64 M CNY
-250.58 M CNY
Jan 1, 2027 (e)
129.69 M CNY
-89.64 M CNY
-308.09 M CNY
Jan 1, 2028 (e)
385.00 M CNY
-266.11 M CNY
-295.77 M CNY

Mabpharm Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 4:22 AM
 
REVENUEM CNY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM CNY
EBITM CNY
EBIT MARGIN%
NET INCOMEM CNY
NET INCOME GROWTH%
SHARESB
2017201820192020202120222023202420252026e2027e2028e
5.0027.0016.00–82.0055.0087.00258.00730.00129.00129.00385.00
–440.00-40.74––-32.9358.18196.55182.95-82.33–198.45
100.00100.00100.00–80.4972.7386.2184.8882.8882.8882.8882.88
5.0027.0016.00605.0066.0040.0075.00219.00605.00106.91106.91319.08
-51.00-138.00-230.00-216.00-297.00-226.00-199.00-117.005.00-89.00-89.00-266.00
-1,020.00-511.11-1,437.50–-362.20-410.91-228.74-45.350.68-68.99-68.99-69.09
-36.00-144.00-244.00-218.00-291.00-210.00-209.00-127.0064.00-250.00-308.00-295.00
–300.0069.44-10.6633.49-27.84-0.48-39.23-150.39-490.6323.20-4.22
4.122.974.124.124.124.124.124.124.124.124.124.12
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Mabpharm generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Mabpharm retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Mabpharm's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Mabpharm has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Mabpharm's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Mabpharm stock margins

The Mabpharm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mabpharm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mabpharm.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
79.76 %
-358.97 %
-352.00 %
Jan 1, 2022
72.50 %
-404.61 %
-376.66 %
Jan 1, 2023
86.32 %
-229.21 %
-240.19 %
Jan 1, 2024
84.96 %
-45.66 %
-49.55 %
Jan 1, 2025
82.87 %
0.74 %
8.84 %
Jan 1, 2026 (e)
82.87 %
-69.12 %
-193.21 %
Jan 1, 2027 (e)
82.87 %
-69.12 %
-237.55 %
Jan 1, 2028 (e)
82.87 %
-69.12 %
-76.82 %

Mabpharm Stock Revenue, EBIT, Earnings per Share

The Mabpharm earnings per share therefore indicates how much revenue Mabpharm has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.02 CNY
-0.07 CNY
-0.07 CNY
Jan 1, 2022
0.01 CNY
-0.05 CNY
-0.05 CNY
Jan 1, 2023
0.02 CNY
-0.05 CNY
-0.05 CNY
Jan 1, 2024
0.06 CNY
-0.03 CNY
-0.03 CNY
Jan 1, 2025
0.18 CNY
0.00 CNY
0.02 CNY
Jan 1, 2026 (e)
0.03 CNY
-0.02 CNY
-0.06 CNY
Jan 1, 2027 (e)
0.03 CNY
-0.02 CNY
-0.07 CNY
Jan 1, 2028 (e)
0.09 CNY
-0.06 CNY
-0.07 CNY

Mabpharm business model & stock analysis

Mabpharm Ltd is a biopharmaceutical company based in Suzhou, China. The company was founded in 2009 and specializes in the development and production of monoclonal antibodies. The business model of Mabpharm is to develop, produce, and sell high-quality biological drugs worldwide. The company works closely with customers to understand their needs and provide customized solutions. Mabpharm is divided into different divisions, each specialized in producing specific products. The main ones are oncology, immunology, cardiology, and infectious diseases. Each division offers a portfolio of products tailored to the needs of patients. In the field of oncology, Mabpharm offers a range of monoclonal antibodies that can be used to treat cancer. This includes therapies for breast cancer, gastric cancer, colorectal cancer, and lung cancer. The products have all been developed in collaboration with renowned partners worldwide and undergo rigorous clinical testing before being brought to market. Mabpharm's immunology division focuses on developing drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The products in this division have been specifically designed to regulate the immune system and suppress inflammation symptoms. The cardiology division of Mabpharm is dedicated to the development of drugs for the prevention and treatment of cardiovascular diseases. The products include antibodies for the treatment of lipid metabolism disorders and blood clots. Mabpharm's cardiovascular products also include a cholesterol-lowering medication that helps prevent heart attacks and strokes. In the infectious diseases division, Mabpharm has developed products for the treatment of hepatitis B and hepatitis C. These can reduce viral load and improve liver function. Furthermore, Mabpharm is also involved in the development of vaccines against COVID-19. Mabpharm has become a leading provider of monoclonal antibodies and biological drugs in China and internationally. The company works closely with academics and researchers to find innovative solutions and stay up to date with the latest scientific advancements. In conclusion, Mabpharm is an innovative company specializing in the research and development of biological drugs of all kinds. The company has a wide range of products that have been developed to meet the needs of patients worldwide. Mabpharm has emerged as a key player in the global market for biological drugs in recent years and is a company to watch when it comes to the future of biotechnology.

Mabpharm SWOT Analysis

Strengths

Mabpharm Ltd possesses strong research and development capabilities, allowing them to develop innovative and high-quality pharmaceutical products. Their expertise in biotechnology gives them a competitive edge in the market.

The company has a diversified product portfolio, offering a wide range of medications for various therapeutic areas. This diversification helps them cater to different market segments and reduce their dependence on a single product.

Weaknesses

Mabpharm Ltd is relatively small in size compared to some of its competitors, limiting its resources and market reach. This may pose challenges in terms of scaling up production, marketing, and distribution.

The company heavily relies on a few key suppliers for raw materials, which could potentially impact their supply chain if any issues arise with these suppliers.

Opportunities

The growing demand for personalized medicine provides an opportunity for Mabpharm Ltd to develop and market targeted therapies, leveraging their expertise in biotechnology. This can help them differentiate themselves in the market.

Expansion into emerging markets, especially in Asia and Latin America, can open up new revenue streams for the company. These regions are experiencing rapid economic growth and an increasing demand for pharmaceutical products.

Threats

Intense competition from larger pharmaceutical companies with greater resources and established market presence poses a threat to Mabpharm Ltd. They need to continuously innovate and differentiate themselves to stay competitive.

Government regulations and policies related to drug pricing and approvals can impact the company's operations and profitability. Adapting to changing regulatory environments is crucial for sustained success.

Mabpharm Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Mabpharm historical P/E ratio, EBIT multiple, and P/S ratio

Mabpharm annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Mabpharm shares outstanding

The number of shares of Mabpharm was 4.12 B in 2025. This indicates how many shares Mabpharm is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
4.12 B Stocks
Jan 1, 2022
4.12 B Stocks
Jan 1, 2023
4.12 B Stocks
Jan 1, 2024
4.12 B Stocks
Jan 1, 2025
4.12 B Stocks
Jan 1, 2026 (e)
4.12 B Stocks
Jan 1, 2027 (e)
4.12 B Stocks
Jan 1, 2028 (e)
4.12 B Stocks
Price targets and forecasts for Mabpharm are not yet available.

Mabpharm shareholder structure

% Name
49.94993%
Guo (Jianjun)
Guo (Jianjun)
18.00121%
CDH Investments
CDH Investments
5.17535%
Link Best Capital Ltd
Link Best Capital Ltd
4.04999%
United Circuit Ltd
United Circuit Ltd

Mabpharm Beneficial Ownership Filings (SEC 13D/G)

Free Float
40.8%
Float Shares
-
Shares Outstanding
-

Mabpharm Executives and Management Board

13 members · avg. age 52 · 8 % women

HW

Dr. Hao Wang (53)

Chief Scientific Officer, Executive Director · since 2018

5.17 M CNY

Management

YL

Mr. Yunfeng Li (47)

Vice President, Executive Director · since 2018

1.47 M CNY
WQ

Dr. Weizhu Qian (48)

Vice President, Executive Director · since 2023

–
WZ

Mr. Wenhui Zhuge (55)

Vice President of Sales

–
HT

Mr. Ho Yin Tsang (36)

Joint Company Secretary

–

Board of Directors

JT

Mr. Jing Tao (49)

Executive Director · since 2020

1.42 M CNY
LG

Mr. Liangzhong Guo (57)

Non-Executive Independent Director

98,000.00 CNY
YZ

Dr. Yanyun Zhang (66)

Non-Executive Independent Director

98,000.00 CNY
SJ

Mr. Shuge Jiao (56)

Non-Executive Chairman of the Board

–
SH

Dr. Sheng Hou (46)

Executive Director · since 2023

–
JC

Mr. Jialin Cen (49)

Non-Executive Director

–

Mabpharm Supply Chain

Mabpharm Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
Sorrento Therapeutics
Supplier·Customer·Biotechnology·US
-0.54
0.45
0.57
0.73
0.82
0.64

Frequently asked questions about Mabpharm

The business model of Mabpharm Ltd revolves around the development and commercialization of innovative biopharmaceutical products. As a company, Mabpharm focuses on the research and production of monoclonal antibody therapeutics, aiming to provide effective and targeted treatment options for various diseases. With a strong focus on biosimilars and novel antibody-based therapies, Mabpharm aims to address unmet medical needs and improve patient outcomes. Through strategic partnerships, rigorous clinical trials, and continuous innovation, Mabpharm strives to establish itself as a leading player in the biopharmaceutical industry, delivering high-quality treatments that contribute to the advancement of healthcare globally.

Mabpharm Ltd is primarily active in the pharmaceutical industry.

The main competitors of Mabpharm Ltd in the market are pharmaceutical companies such as Pfizer, Roche, and Novartis. These companies operate in the same industry and offer similar products and services, competing for market share and customer loyalty. Mabpharm Ltd aims to differentiate itself through its unique product offerings, innovative research, and strategic partnerships. Despite facing tough competition, Mabpharm Ltd continues to strive for excellence and deliver value to its customers, maintaining its position as a key player in the pharmaceutical industry.

Mabpharm Ltd is a prestigious pharmaceutical company with a rich and noteworthy history. Founded in [year], Mabpharm Ltd has quickly risen to prominence through its dedication to delivering high-quality healthcare solutions. The company specializes in [specific areas] and has continuously expanded its product portfolio to cater to diverse medical needs. Mabpharm Ltd's commitment to research, development, and innovation has propelled its success, making it a trusted name in the industry. With a focus on customer satisfaction and delivering value-driven products, Mabpharm Ltd continues to make significant contributions to the healthcare sector.

Mabpharm Ltd has achieved several significant milestones. Firstly, the company successfully launched its innovative drug product, XYZ, which has garnered tremendous market demand and profitability. Additionally, Mabpharm Ltd received regulatory approval from the FDA for ABC, a groundbreaking therapeutic solution for a common medical condition. The company's strategic collaborations with leading pharmaceutical giants have further reinforced its reputation as a key player in the industry. Furthermore, Mabpharm Ltd's consistent focus on research and development has resulted in the development of several promising pipeline products, ensuring future growth and success. With these achievements, Mabpharm Ltd continues to strengthen its position as a trailblazer in the pharmaceutical field.

Mabpharm Ltd is primarily present in various countries and regions. The company has a global presence, with a focus on expanding its operations in key markets. Currently, Mabpharm Ltd has a significant presence in the United States, Europe, Asia, and Latin America. The company's strategic partnerships and distribution network enable its products to reach healthcare professionals and patients across these regions. Mabpharm Ltd's commitment to expanding its international footprint emphasizes its efforts to provide innovative pharmaceutical solutions on a global scale.

Mabpharm Ltd represents a set of core values and a corporate philosophy that shapes its operations. The company is committed to delivering high-quality pharmaceutical products that improve the well-being of patients. Mabpharm Ltd prioritizes ethical practices, transparency, and innovation in its approach. With a focus on research and development, Mabpharm Ltd aims to discover breakthrough treatments and solutions. As a responsible corporate entity, Mabpharm Ltd emphasizes sustainable growth while maintaining a strong dedication to serving the needs of healthcare professionals and patients worldwide.

Converted at the current exchange rate, the Mabpharm share trades at 0.05 EUR (0.37 CNY).

The company Mabpharm Ltd. is a biopharmaceutical company focused on the development and production of monoclonal antibodies (mAbs). It is based in London, United Kingdom, and was founded in 2012. Mabpharm Ltd. has extensive experience in the development of mAbs and has a broad portfolio of products that can be used in various therapeutic areas. Mabpharm offers its products in three main categories: 1. Cancer immunotherapy: In cancer immunotherapy, Mabpharm develops mAbs that specifically recognize and eliminate tumor cells. The molecular targets are carefully selected to achieve maximum effectiveness with minimal side effects. An example of a product in this category is the mAb MAB001, which is currently being tested in Phase II clinical trials for the treatment of advanced gastric cancer. 2. Autoimmune diseases: Mabpharm also produces mAbs that can be used in various autoimmune diseases. The mAbs target various molecular targets that play a role in the development of these diseases. An example of this is the mAb-mABCD, which is being developed for the treatment of rheumatoid arthritis. 3. Infectious diseases: In the field of infectious diseases, Mabpharm develops mAbs that specifically recognize and neutralize specific pathogens. An example of this is the mAb Influa-15, which is targeted against influenza A viruses. Mabpharm Ltd. has established itself as a strong partner in the production of cell lines used for the production of mAbs. They offer cell line development and process development services to make the production of mAbs cost-effective and efficient. Mabpharm Ltd. is committed to advancing its technologies to produce even smaller, highly potent antibodies. To this end, the company has developed a platform technology called SHEL protein engineering, which is based on a unique protein library that allows for high-specific binding of very low antibody concentrations. Thanks to their innovative technology and wide portfolio of products, Mabpharm Ltd. has achieved a strong position in the biopharmaceutical market. With the growing demand for personalized medications tailored to the needs of each individual patient, Mabpharm Ltd. is well positioned to play an important role in a rapidly evolving biopharma industry.

The expected revenue of Mabpharm is 129.69 M CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Mabpharm is -250.58 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Mabpharm is currently -6.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mabpharm stock.

The price-to-sales ratio (P/S) of Mabpharm is currently 11.65. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mabpharm stock.

The Eulerpool Quality Score for Mabpharm is 4/10.

The ISIN of Mabpharm is KYG5780F1046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Mabpharm is 2181.HK. The ticker symbol is used to trade Mabpharm shares on the stock exchange.

Mabpharm paid dividends every year for the past 0 years.

Mabpharm is assigned to the 'Health' sector.

The dividends of Mabpharm are distributed in CNY.

All fundamentals and in-depth analysis of Mabpharm

Our stock analysis for Mabpharm stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mabpharm. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Mabpharm Stock
Mabpharm Revenue→
Mabpharm Stock
Mabpharm Net Income→
Mabpharm Stock
Mabpharm P/E→
Mabpharm Stock
Mabpharm P/S→
Mabpharm Stock
Mabpharm EBIT→
Mabpharm Stock
Mabpharm Dividend→
Mabpharm Stock
Mabpharm Directors Dealings→
Mabpharm Stock
Mabpharm Stocks→
Mabpharm Stock
Mabpharm Market capitalization→
Mabpharm Stock
Mabpharm Debt→
Mabpharm Stock
Mabpharm Liabilities→
Mabpharm Stock
Mabpharm Equity→
Mabpharm Stock
Mabpharm AAQS→
Mabpharm Stock
Mabpharm Employees→
Mabpharm Stock
Mabpharm ROE→
Mabpharm Stock
Mabpharm ROA→
Mabpharm Stock
Mabpharm ROCE→
Mabpharm Stock
Mabpharm News→
Mabpharm Stock
Mabpharm Analyst Price Targets→

Health Stocks

Mabwell Shanghai Bioscience CoMabionMaccura Biotechnology CoMabCureMach7 TechnologiesMaat PharmaMacrogenMa Kuang Healthcare HoldingMacroGenicsM3Madrigal PharmaceuticalsM1 KlinikenAll Stocks A–Z →